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Abstract
Little is known about rates of joint bleeding among females with FVIII/FIX deficiency or 
hemophilia carriers. In a cross-sectional study, we tested the hypothesis that females with FVIII or 
FIX deficiency enrolled in the Universal Data Collection (UDC) project had a reduced mean 
overall joint range of motion (ROM) compared with historic controls from the Normal Joint 
Study. Demographics, clinical characteristics, and joint ROM measurements on 303 females 
without a bleeding disorder and 148 females with FVIII and FIX deficiency, respectively, between 
the ages of 2–69 years and a body mass index (BMI) ≤35 were compared. Multivariate linear 
regression was performed with the overall joint ROM (sum of the right and left ROM 
measurements of five joints) as the dependent variable and FVIII or FIX activity as the 
independent variable adjusting for age, race, BMI, and number of joint bleeds reported over the 
last 6 months. As FVIII and FIX activity decreased, the mean overall joint ROM became reduced 
and in most cases was significantly lower than that of the controls regardless of age and clinical 
hemophilia severity. Further investigation of reduced joint ROM as evidence of subclinical joint 
bleeding in females with FVIII and FIX deficiency is warranted.
Introduction
Hemophilia A and B are X-linked recessive disorders caused by mutations in the F8 and F9 
genes, respectively, resulting in deficient residual factor activity with bleeding symptoms 
correlating to the severity of deficiency. Given the hemizygous nature of X-linked disorders, 
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mostly males are affected while females are more commonly heterozygous for the gene 
mutation, and are typically referred to as carriers. There are approximately 80,000 
hemophilia carriers in the United States (U.S.) based on the premise that approximately 95% 
of mothers of males with hemophilia are carriers and there are at least four hemophilia 
carriers related to a single male with hemophilia [1]. Over the last decade, hemophilia 
carriers are increasingly using the Hemophilia Treatment Center (HTC) for their medical 
care. From 2002 to 2010, there was a 62% absolute rise in the number of hemophilia carriers 
being managed at HTCs [2]. The proportion of female patients receiving care at HTCs has 
grown to > 30% and hemophilia carriers are the second largest group after females with von 
Willebrand disease (VWD).
Hemophilia A and B carriers, even those with normal hemostatic levels (> 40%), might have 
an increased bleeding tendency, including but not limited to prolonged skin bleeding, heavy 
menstrual bleeding, oral bleeding and excessive bleeding following dental procedures, and 
surgery [3–5]. Joint bleeding is classically associated with males with hemophilia, and it has 
been self-reported by 8%–16% of hemophilia carriers [3,4]. Repeat bleeding into the joint 
can lead to chronic inflammation, ultimately leading to limited joint mobility, and reduced 
joint range of motion (ROM). Although joint bleeding contributes to the majority of 
morbidity in affected males, less is known about the prevalence of joint damage or 
destruction in hemophilia carriers. There are no studies to date evaluating joint abnormalities 
in hemophilia carriers and interrogation of the prevalence of reduced joint ROM, a possible 
surrogate for subclinical joint bleeding, has not been performed.
In response to the lack of a centralized dataset for persons with bleeding disorders, the 
Centers for Disease Control (CDC) created a national public health surveillance project 
called the Universal Data Collection (UDC) system. The UDC project was performed with 
the assistance of the federally funded HTCs in the United States, laypeople with bleeding 
disorders and the CDC. From 1998 to 2011, the HTC staff obtained informed consent from 
each UDC study participant and collected a standard set of clinical data as well as a plasma 
specimen for surveillance of potential blood-borne infections. Data collected included 
demographics, standardized joint range of motion, and limited bleeding and infectious 
disease history. The accuracy of the UDC project relies on the CDC infrastructure and 
oversight. This dataset has been maintained by the CDC and requires central review and 
revision of all proposals and data analysis before permission for submission for external 
publication.
Due to the lack of data on joint range of motion in healthy males and females across the life 
span, the CDC performed a cross-sectional study (Normal Joint Study) to establish 
normative joint range of motion data for comparison with persons with bleeding disorders 
[6]. Healthy males and females were recruited across multiple age groups (age 2–69), 
ethnicities, and BMI. Subjects with conditions that might limit joint range of motion were 
excluded including but not limited to anyone with Ehler Danlos Syndrome, BMI > 35, 
pregnancy, neurologic/rheumatologic disorders, and personal or a family history of a 
bleeding disorder. Measurements were collected by trained physical therapists using the 
same methods used for the UDC project.
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To address the gap in knowledge between the high rate of self-reported joint bleeding and 
the perception that hemophilia carriers are clinically asymptomatic, we tested the hypothesis 
that females with FVIII or FIX deficiency enrolled in the Universal Data Collection (UDC) 




We used a cross-sectional study design limiting analysis to female UDC participants age 2 
years or older with FVIII or FIX deficiency. Females with FVIII or FIX deficiency were 
enrolled in the UDC by staff in one of the 136 federally funded HTCs in the United States. 
Participants with a BMI > 35 were excluded from the analysis because they were excluded 
from the control study; for participants with multiple visits, joint ROM data collected during 
the last comprehensive care visit were used. During the annual visit for the UDC study, 
participants had their height and weight measured in light clothing without shoes, and 
bilateral ROM measurements on five joints (hips, knees, shoulders, elbows, and ankles) 
were performed by a physical therapist or other trained health care provider according to 
detailed guidelines provided in a reference manual and training video (http://www.cdc.gov/
ncbddd/video/jointrom/intro/) supplied by the Centers for Disease Control and Prevention 
(CDC). Participant body position for their joint measurements was standard and as follows: 
sitting for ankle dorsiflexion and plantarflexion and for elbow pronation and supination; 
supine for knee flexion, extension, and hyperextension, for hip flexion, for shoulder flexion, 
and for elbow flexion, extension, and hyperextension; and side lying for hip extension. Each 
joint was moved passively to its full extent, and end-point measurements were made to the 
nearest degree using a standard goniometer. The joints in which a bleed has occurred within 
24 hrs or whose motion is restricted for another medical reason, such as an immobilization 
device or pregnancy (local determination made clinically if pregnant and unable to perform 
joint ROM), were not measured or included in the analysis. All health care providers 
performing these measurements were trained and certified by one of 12 regional physical 
therapists, who had previously received centralized training. Among the measured ROM 
data, 91% were collected by licensed physical therapists.
Demographic and clinical information was obtained from UDC study participants from the 
Hemophilia Treatment Centers Network during the annual care visit and was recorded using 
two standardized data collection forms. The forms were created to capture critical data on 
males with hemophilia. Females with FVIII or FIX deficiency were allowed to be included 
in the UDC dataset based on local physician preference. A registration form was completed 
at the time of enrollment for a new participant and included month and year of birth, age at 
first HTC visit, factor deficiency type (FVIII or FIX), and factor activity. Hemophilia 
severity was categorized as mild if the factor activity was > 5% and < 40%, moderate if ≥1% 
and 5% and severe if < 1% of normal. Additionally, females (presumed to be hemophilia 
carriers) with normal factor activity (≥40% and reported by the local HTC) were included in 
enrollment. Race and ethnicity were based on participant self-report and categorized in 
accordance with United States. census reporting. HTC staff used the annual visit form to 
Sidonio et al. Page 3













record current treatment and outcome data. HTC use by participants was categorized as 
frequent (one or more visits per year), infrequent (every 2–3 years), rare (visits every 4 or 
more years) or first visit according to the frequency of HTC visits during the previous 
annual period. If the participant infused clotting factor on a regular basis (e.g., two-three 
times a week) to prevent bleeding and the infusions were expected to continue indefinitely, 
she was considered to be on continuous prophylaxis treatment.
Female participants were assessed for the presence of neutralizing inhibitors based on local 
physician preference. Participants with an inhibitor titer of ≥1 Bethesda unit within a year 
before the annual comprehensive care visit were classified as having an inhibitor. Clinic and 
hospital records were reviewed by the local HTC to determine whether or not orthopedic 
surgery has been performed any joints during the previous year. Orthopedic surgical 
procedures were defined as arthrodesis, synovectomy, joint replacement, and other. None of 
the study participants reported orthopedic procedures thus all were included in analysis. 
Participants were asked to recall the total number of joint bleeds over the previous 6-month 
period during their annual visit.
Participants from The Normal Joint Study dataset [6] were used as controls for this study. 
This descriptive study determined measurements of female volunteers aged 2 to 69 years 
recruited in a variety of settings across the United States. Study exclusions comprised 
conditions that could potentially limit joint mobility, such as but not limited to BMI > 35, 
neurologic disorders impairing joint ROM, recent orthopedic injury, inability to ambulate 
without assistance, connective tissues disorder, a history of joint surgery, pregnancy, and 
waist to hip ratio > 1. Weight and height were measured in light clothing and BMI was 
calculated as weight in kilograms divided by the height in meters squared. Nine licensed 
physical therapists participated in a training session and were validated within < 5° in 
measurement. Joint ROM technique was identical to that used by licensed physical 
therapists and healthcare providers in the HTC Network.
Primary and secondary outcome assessment
The primary outcome was the mean overall joint ROM. The overall joint ROM was 
calculated for each female participant and was the sum of all flexion and extension 
(including hyperextension) measurements taken on all 10 joints in passive motion. Normal 
joint ROM values were derived from females in the Normal Joint Study. The sum of the 
overall joint ROM was used to calculate the mean overall joint ROM as the mean of all 
flexion and extension (including hyperextension) measurements for all females with FVIII 
or FIX deficiency from the UDC and for all normal females from the Normal Joint Study.
The secondary outcome was the joint ROM difference, defined as the difference between the 
sum of the mean overall joint ROM for females with FVIII or FIX deficiency and the sum of 
the mean overall joint ROM for normal females. Negative values for the joint ROM 
difference meant that affected females had reduced joint mobility relative to that of the 
healthy females.
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Results were displayed as mean overall joint ROM with 95% confidence interval (CI) and P-
values by age group and factor deficiency. Comparison of the mean overall joint ROM 
between females with FVIII or FIX deficiency and normal control females was assessed for 
statistical significance using the Wilcoxon-rank-sum test. The decision to analyze the 
females with FVIII separately from those with FIX deficiency was based on the a priori 
concern in discrepancy in bleeding phenotype. To account for potential confounders, 
multivariate linear regression was performed using the General Linear Model (GLM) 
procedure with the mean overall joint ROM as the dependent variable and the factor 
deficiency type and severity as the independent variable adjusting for race (white, non-
white) and BMI (continuous). Confounding was assessed using a backward elimination 
strategy. Separate linear regression models were created stratifying by age (2–9, 10–19, 20–
44, and 45–69 years) and hemophilia clinical severity (normal FVIII activity, mild, 
moderate, and severe FVIII deficiency). Hypothesis tests were two-tailed, and significance 
was based on achievement of a P-value < 0.05. All analyses were performed using SAS 
Version 9.3 statistical software (SAS Institute, Cary, NC).
Results
Demographic and clinical characteristics
Tables I and II present selected demographic and clinical characteristics of females with 
FVIII or FIX deficiency, respectively, who participated in the UDC between 1998 and 2010. 
A total of 670 females were enrolled in the UDC dataset. Of the 670 females identified with 
FVIII or FIX deficiency; 21% (144/670) of the females were removed because of lack of 
verification of factor deficiency type and 14% (75/526) of the females were removed due to 
being very obese (BMI > 35) or outside the age range studied in the Normal Joint Study. 
Descriptive statistics and joint ROM analysis were performed on 303 and 148 females with 
FVIII or FIX deficiency, respectively, between the ages of 2–69 years for comparison with 
the control group (Tables I and II). The majority of the females with FVIII or FIX deficiency 
were FVIII deficient (67%, 303/451), white (70% and 76%), and young adult age (median 
age of 25.5 and 23.5 years), respectively. In addition, 59% (147/249) and 61% (70/115) of 
the females with FVIII or FIX deficiency, respectively, were normal or underweight. The 
majority, 63% (158/249) and 61% (73/119), of females with FVIII or FIX deficiency, 
respectively, frequently used (visited their HTC at least every two years) their local HTC 
and 6% (15/249) and 4% (5/119) reported use of continuous factor prophylaxis, 
respectively. Finally, the percentage of females with FVIII deficiency reporting ≥1 joint 
bleed in the last 6 months before the annual visit increased as clinical severity worsened 
ranging from 0%, 15%, 36%, and 54% in normal, mild, moderate, and severe FVIII 
deficient states, respectively. A similar relationship was seen in females with FIX deficiency 
with 8%, 2%, 33%, and 37% reporting at least one joint bleed in normal, mild, moderate, 
and severe FIX deficient states, respectively.
When the joint ROM data in females with FVIII or FIX deficiency was stratified by whether 
the exam was performed by a licensed physical therapist or by some other trained health 
care provider, there was no significant difference in mean overall joint ROM. None of the 
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female participants reported undergoing immune tolerance therapy for inhibitor 
development, and none of the final evaluable participants were reported an orthopedic 
surgical procedure.
Joint ROM in females with FVIII deficiency
Table III summarizes the mean overall joint ROM among females with FVIII deficiency by 
age and factor activity. Females with FVIII deficiency had reduced joint ROM compared 
with controls. As FVIII activity decreased, the mean overall joint ROM became reduced and 
in most cases was significantly lower than that of the controls. There was a statistically 
significant reduction in mean overall joint ROM in all severities and age groups compared 
with participants in the Normal Joint Study, except in females 9–19 or 45–69 years of age 
with FVIII ≥1% and ≤5%, as well as in females 2–8 or 45–69 years with FVIII ≥40% (Table 
III). Using the joint ROM difference, loss of total joint ROM was noted in children as early 
as ages 2–8 years of age, becoming more limited with increasing clinical hemophilia 
severity (Table IV). There was a significant correlation between hemophilia severity and 
mean overall joint ROM in females with FVIII deficiency (P < 0.0001), except for females 
with moderate FVIII deficiency 45 years of age or older (Fig. 1). Multivariate analysis 
showed that females with FVIII activities of <1%, ≥1% and ≤5%, and >5% and <40% had a 
significantly reduced mean overall joint ROM compared with normal female controls, 
stratifying by age and clinical hemophilia severity and controlling for BMI and race (data 
not shown). In addition, the mean overall joint ROM was significantly lower in females with 
FVIII activities ≥1% and ≤5%, and <1% compared with females with FVIII activity ≥40%, 
adjusted for BMI, age, race, and joint bleeds over the last 6 months (data not shown).
Joint ROM in females with FIX deficiency
In females with FIX deficiency, we were limited on the depth of analysis that could be 
performed due to small sample size. Results indicated a statistically significant reduction in 
mean overall joint ROM in all severities and age groups compared with participants in the 
Normal Joint Study (P < 0.0001), except in females of all age groups with FIX ≥1% and 
≤5%. As presented in Table V, the joint ROM difference was reduced compared with 
normal controls across age groups and clinical hemophilia severity, but the trend for loss of 
joint ROM was not linear. In addition, there was no statistically significant correlation 
between hemophilia severity and mean overall joint ROM.
Discussion
We were able to demonstrate that females with FVIII or FIX deficiency enrolled in the UDC 
project had a reduced mean joint ROM compared with historic controls from the Normal 
Joint Study. To our knowledge, this study is the first to report findings on joint abnormalities 
in females with FVIII or FIX deficiency and is the largest repository of females that are 
likely hemophilia carriers.
Our analyses suggested that subclinical joint bleeding might be occurring before adolescent 
years in both females with FVIII or FIX deficiency. If this is true, then further investigation 
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is warranted into the mechanism of reduction of ROM particularly as reduced joint ROM 
was seen with study participants with normal hemostatic activity (> 40%).
The rate of self-reported joint bleeds was high amongst FVIII and FIX deficient females. 
Our study demonstrates that a substantial number of females with mild and moderate FVIII 
and FIX deficiency reported at least one joint bleed within the previous 6-month period. 
Soucie et al [6] described > 40% of males with mild and moderate hemophilia self-reporting 
a joint bleed in the same time period, and approximately 35% of males with severe 
hemophilia reporting a joint bleed. The reason behind the discrepancy between severe and 
mild/moderate hemophiliacs reporting a joint bleed was the result of a higher percentage of 
use of factor prophylaxis. Regarding females with severe FVIII/FIX deficiency, we would 
expect a higher than reported percentage of females with severe FVIII or FIX deficiency to 
be on either primary or secondary factor prophylaxis. In the UDC cohort, only 25% and 27% 
of females with severe FVIII and FIX deficiency, respectively, reported the use of 
continuous factor prophylaxis. The reason for a small fraction of females with severe 
FVIII/FIX deficiency on factor prophylaxis might be due to multiple factors, including 
delayed identification of their disease due to their gender, and physician perception of 
reduced bleeding phenotype.
The extent of joint ROM reduction in females with FVIII or FIX deficiency, particularly 
those with mild deficiency, was unexpected. Soucie et al. [6] described that physiologic 
hypermobility, the ability to flex and extend beyond the established normal joint range, was 
lost by age 8, 8.6, and 12 years in males with severe, moderate, and mild hemophilia, 
respectively. Hypermobility was lost in all hemophilia severities in females by 8 years of 
age. The extent of reduction of joint ROM may be explained by the fact that females 
recruited for this study might have an increased bleeding tendency compared with the 
general population, as most hemophilia carriers are not routinely followed at HTCs, unless 
there is an increased bleeding tendency. In support of this notion, >60% of the females with 
FVIII or FIX deficiency recruited for the UDC study used their HTC frequently (Tables I 
and II) compared with >76% in males with FVIII or FIX deficiency [7]. Furthermore, the 
extent in reduction of joint ROM could also be the result of under-recognized early bleeding 
symptoms and late verification of hemophilia carrier status. We have demonstrated that the 
average age of identification of hemophilia carrier status was > 18 years of age in 78% (n = 
47) of surveyed hemophilia carriers from a patient advocacy group [8].
In hemophilia A and B carriers, the mean FVIII level is ~50% of the normal mean, or one 
half of the expected value for a group of non-carrier women, potentially putting women at 
increased bleeding risk. There is a likely continuum of bleeding phenotypes starting within 
the low end of the normal range and extending into the abnormal [9]. In females with FVIII 
deficiency, it should be noted that FVIII activity increases with age, and the levels of this 
cohort may have been low enough when they were younger to put them at greater risk of 
joint bleeding compared to in life.
This study has, however, several limitations. First, females with FVIII or FIX deficiency 
were enrolled based on local physician preference. It is unknown what the motivators of the 
local physician were in consideration of enrollment of hemophilia carriers into the UDC 
Sidonio et al. Page 7













study. Because not all the HTCs enrolled females with FVIII or FIX deficiency, there is 
likely selection bias. We were not able to determine whether the analyzed cohort was 
different compared with females with FVIII or FIX deficiency that do not receive care in 
HTCs. As it is likely that mostly symptomatic females with FVIII or FIX deficiency were 
enrolled in the UDC, one would expect a slightly higher than expected reduction in mean 
overall joint ROM. However, this study reports joint abnormalities in this population and it 
is consistent with the self-reported joint bleeding rate of 8%–16% in previous studies [3,4]. 
Second, this study lacked universal genetic verification of hemophilia carrier status (FVIII 
or FIX deficiency). In this UDC cohort, 17% of all the females identified were genetically 
verified as carriers of hemophilia, while more than 33% of the females with severe FVIII or 
FIX deficiency were genetically confirmed. It is highly likely that those enrolled were 
carriers of hemophilia. Due to privacy protection and wide HTC distribution of the 
participants, however, we were not able to link the UDC data of the patients to those of their 
male relatives. During quality control evaluation of the data, we found none of the females 
with FVIII or FIX deficiency had VWD listed as a diagnosis, and all of reported factor 
activities correlated with hemophilia clinical severity classification.
In summary, females with FVIII or FIX deficiency had evidence of reduced overall joint 
ROM noted as early as the pre-teen years. This study is the first step in demonstrating that 
subclinical or asymptomatic joint damage occurs in females with FVIII or FIX deficiency 
regardless of the hemophilia clinical severity. Investigation into whether these joint 
abnormalities correlate with magnetic resonance imaging changes is underway.
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Predicted mean overall range of motion (ROM) by age and clinical severity, for 2- to 69-
year old females with FVIII deficiency. Graph was created using separate linear regression 
models for normal FVIII activity, and for mild, moderate, and severe FVIII deficiency 
adjusted for race and body mass index (BMI). Mean overall ROM was calculated by setting 
categorical variables equal to the reference value and by using the severity group mean for 
the continuous variable BMI. Normal activity (>40% FVIII); Mild deficiency (>5%–40%); 
Moderate deficiency (1%–5%); Normal Study (normal females from Normal Joint Study).
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